康寧傑瑞(09966.HK)續挫18%失守250天線成交急增
康寧傑瑞製藥-B(09966.HK)繼昨天回吐4.7%後,今早股價回升至12.6元無以為繼,掉頭低見8.7元,最多挫30%,現報10.2元,挫18%,成交急增至3,785萬股,為近半年來罕見,涉資3.72億元。
康寧傑瑞及石藥集團(01093.HK)上周公布,由康寧傑瑞旗下江蘇康寧傑瑞生物製藥及石藥集團附屬上海津曼特生物科技,合作開發重組人源化抗HER2雙特異性抗體注射液KN026,近日獲國家藥監局授予突破性治療認定,擬定適應症為聯合化療藥物,用於一線標準治療(曲妥珠單抗聯合化療)失敗的HER2陽性局部晚期、復發或轉移性的胃癌,包括胃食管結合部腺癌。
其他醫藥股以藥明康德(02359.HK)、藥明巨諾(02126.HK)、藥明生物(02269.HK)、維亞生物(01873.HK)、康方生物(09926.HK)及諾誠健華(09969.HK)表現較差,股價續跌逾2%-4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.